目的:Selinexor是一种新型的XPO1抑制剂,抑制肿瘤抑制蛋白和癌蛋白mRNA的输出,导致细胞周期停滞和癌细胞凋亡。虽然selinexor目前被FDA批准用于治疗多发性骨髓瘤,令人信服的临床前和早期临床研究揭示了selinexor治疗血液系统和非血液系统恶性肿瘤的疗效,包括肉瘤,胃,膀胱,前列腺,乳房,卵巢,皮肤,肺,和脑癌。当前对selinexor的评论主要强调了其在血液恶性肿瘤中的用途;然而,本文旨在总结selinexor治疗实体瘤的最新证据。
方法:在PubMed和KaryopharmTherapeutics网站上进行有关selinexor和非血液系统恶性肿瘤临床前和临床试验的相关文献检索。
结果:这篇综述提供了证据,证明selinexor是一种在非血液系统恶性肿瘤中单独使用或与其他抗癌药物联合使用的有前途的药物。
结论:需要进一步临床研究selinexor治疗实体恶性肿瘤。
OBJECTIVE: Selinexor is a novel XPO1 inhibitor which inhibits the export of tumor suppressor proteins and oncoprotein mRNAs, leading to cell-cycle arrest and apoptosis in cancer cells. While selinexor is currently FDA approved to treat multiple myeloma, compelling preclinical and early clinical studies reveal selinexor\'s efficacy in treating hematologic and non-hematologic malignancies, including sarcoma, gastric, bladder, prostate, breast, ovarian, skin, lung, and brain cancers. Current reviews of selinexor primarily highlight its use in hematologic malignancies; however, this
review seeks to summarize the recent evidence of selinexor treatment in solid tumors.
METHODS: Pertinent literature searches in PubMed and the Karyopharm Therapeutics website for selinexor and non-hematologic malignancies preclinical and clinical trials.
RESULTS: This
review provides evidence that selinexor is a promising agent used alone or in combination with other anticancer medications in non-hematologic malignancies.
CONCLUSIONS: Further clinical investigation of selinexor treatment for solid malignancies is warranted.